MediciNova (MNOV) Q4 2024 earnings summary

Executive summary

• Focused on developing MN-166 (ibudilast) for neurological disorders and MN-001 (tipelukast) for fibrotic/metabolic diseases, with a U.S. commercial focus.

• No products approved for commercial sale; revenue generation depends on future regulatory approvals or out-licensing.

• Net loss of $11.0 million for 2024, with an accumulated deficit of $426.8 million as of December 31, 2024.

• Sufficient cash and equivalents ($40.4 million) to fund operations through at least February 2026.

Financial highlights

• 2024 revenues were $0.0 million, down from $1.0 million in 2023 due to a non-recurring milestone payment in the prior year.

• Research, development, and patent expenses increased to $7.2 million (from $5.7 million in 2023), mainly due to MN-166 clinical trial costs.

• General and administrative expenses rose to $5.5 million, driven by higher stock option expense and professional fees.

• Interest income was $1.7 million, slightly lower than 2023 due to lower interest rates.

• No shares were sold under the ATM equity program in 2024 or 2023.

Outlook and guidance

• Expects continued significant net losses for the next several years as development of MN-166 and MN-001 continues.

• 2025 operating cash needs projected at $21.3 million, with similar spending expected in 2026.

• Research and development expenses anticipated to increase moderately in 2025.